Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer

被引:77
|
作者
De Jaeger, K
Seppenwoolde, Y
Boersma, LJ
Muller, SH
Baas, P
Belderbos, JSA
Lebesque, JV
机构
[1] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Nucl Med, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Chest Oncol, NL-1066 CX Amsterdam, Netherlands
关键词
pulmonary function; SPECT; perfusion; tumor response; mean lung dose;
D O I
10.1016/S0360-3016(02)04389-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study changes of pulmonary function tests (PFTs) after radiotherapy (RT) of non-small-cell lung cancer (NSCLC) in relation to radiation dose, tumor regression, and changes in lung perfusion. Methods and Materials: Eighty-two patients with inoperable NSCLC were evaluated with PFTs (forced expiratory volume in 1 s [FEVt] and diffusion capacity [T-L,T-COc]), a computed tomography (CT) scan of the chest, and a single photon emission CT (SPECT) lung perfusion scan, before and 3-4 months after RT. The reductions of PFTs and tumor volume were calculated. The lung perfusion was measured from pre- and post-RT SPECT scans, and the difference was defined as the measured perfusion reduction (MPR). In addition, the perfusion post-RT was estimated from the dose distribution using a dose-effect relation for regional lung perfusion, and compared with the pre-RT lung perfusion to obtain the predicted perfusion reduction (PPR). The difference between the actually measured and the PPR was defined as reperfusion. The mean lung dose (MLD) was computed and weighted with the pre-RT perfusion, resulting in the mean perfusion-weighted lung dose (MpLD). Changes of PFTs were evaluated in relation to tumor dose, MLD, MpLD, tumor regression, and parameters related to perfusion changes. Results: In a multivariate analysis, the total tumor dose and MLD were not associated with reductions of PFTs. Tumor regression resulted in a significant improvement of FEV1 (p = 0.02), but was associated with a reduction of T-L,T-COc. (P = 0.05). The MpLD and the PPR showed a significant (p = 0.01 to 0.04) but low correlation (r = 0.24 to 0.31) with the reduction of both PFTs. The other parameters for perfusion changes, the MPR and reperfusion were not correlated with changes in PFTs. Conclusion: The perfusion-related dose variables, the MpLD or the PPR, are the best parameters to estimate PFTs after RT. Tumor regression is associated with an improvement of FEV1 and a decline of T-L,T-COc. Reperfusion was not associated with an improvement of global pulmonary function. (C) 2003 Elsevier Science Inc.
引用
收藏
页码:1331 / 1340
页数:10
相关论文
共 50 条
  • [31] Treatment Plan Parameters and Toxicity Following Chemoradiotherapy and High-Dose Radiotherapy in Stage III Non-Small Cell Lung Cancer
    De Vries, I. Remmerts
    Ronden, M.
    Bahce, I.
    Dahele, M.
    Spoelstra, F.
    De Haan, P.
    Haasbeek, C.
    Lissenberg-Witte, B.
    Slotman, B.
    Verbakel, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1048 - S1048
  • [32] A PHASE-II STUDY OF HIGH-DOSE EPIRUBICIN IN UNRESECTABLE NON-SMALL-CELL LUNG-CANCER
    SMIT, EF
    BERENDSEN, HH
    PIERS, DA
    SMEETS, J
    RIVA, A
    POSTMUS, PE
    BRITISH JOURNAL OF CANCER, 1992, 65 (03) : 405 - 408
  • [33] Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer
    Gridelli, C
    Rossi, A
    Incoronato, P
    Bruni, GS
    Scognamiglio, F
    Ruffolo, P
    Rinaldi, L
    Bianco, AR
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 37 (06) : 613 - 615
  • [34] Postoperative radiotherapy in non-small-cell lung cancer - Reply
    Baumann, M
    STRAHLENTHERAPIE UND ONKOLOGIE, 1999, 175 (03) : 136 - 137
  • [36] Metabolic imaging in non-small-cell lung cancer radiotherapy
    Geets, X.
    Sterpin, E.
    Wanet, M.
    Di Perri, D.
    Lee, J.
    CANCER RADIOTHERAPIE, 2014, 18 (5-6): : 402 - 405
  • [37] Radiotherapy and targeted therapies in non-small-cell lung cancer
    Girard, N.
    Mornex, F.
    BULLETIN DU CANCER, 2009, 96 (03) : 311 - 319
  • [38] Palliative percutaneous radiotherapy in non-small-cell lung cancer
    Budach, W
    Belka, C
    LUNG CANCER, 2004, 45 : S239 - S245
  • [39] Integration of multimodality imaging in high-dose conformal radiotherapy for non-small cell lung cancer.
    De Jaeger, K
    Seppenwoolde, Y
    Belderbos, JSA
    Boersma, LJ
    van Herk, M
    Lebesque, JV
    ANNALS OF ONCOLOGY, 2000, 11 : 155 - 156
  • [40] High-Dose Pemetrexed in Combination with High-Dose Crizotinib for the Treatment of Refractory CNS Metastases in ALK-Rearranged Non-Small-Cell Lung Cancer
    Gandhi, Leena
    Drappatz, Jan
    Ramaiya, Nikhil H.
    Otterson, Gregory A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) : E3 - E5